U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C22H22ClN5O4S2
Molecular Weight 520.024
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SUPROCLONE

SMILES

CCC(=O)N1CCN(CC1)C(=O)OC2N(C(=O)C3=C2SCCS3)C4=CC=C5C=CC(Cl)=NC5=N4

InChI

InChIKey=IBAUKGNDWVSETP-UHFFFAOYSA-N
InChI=1S/C22H22ClN5O4S2/c1-2-16(29)26-7-9-27(10-8-26)22(31)32-21-18-17(33-11-12-34-18)20(30)28(21)15-6-4-13-3-5-14(23)24-19(13)25-15/h3-6,21H,2,7-12H2,1H3

HIDE SMILES / InChI

Description

Suproclone is a sedative and anxiolytic drug in the cyclopyrrolone family of drugs, developed by the French pharmaceutical company Rhône-Poulenc. The mechanism of action by which Suproclone produces it's sedative and anxiolytic effects is by modulating GABAA receptors

Originator

Rhone-Poulenc Industries S. A.
3

Approval Year

Unknown
149,124

Patents

4220646
1
ACTIVE MOIETY
Structure of SUPROCLONE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966